
iCARDIO Alliance Global Implementation Guidelines on Ischemic Heart Disease 2026

10.4081/cardio.2026.112

Declaration of Interest Report

Fausto J. Pinto (FJP), Martha Gulati (MG), Daniel Caldeira (DC), Clara K. Chow (CKC), Luis Henrique Wolff Gowdak (LHWG), Dipti Itchhaporia (DI), Abdulla Shehab (AS), Gurpreet Singh Wander (GSW), Beth L. Abramson (BLA), Takashi Akasaka (TA), Giuseppe Ambrosio (GA), Alexandra Arias-Mendoza (AAM), Otavio Berwanger (OB), Anastase Dzudie (AD), Evangelos Giannitsis (EG), Rania Hammami (RH), Neil Johnson (NJ), Vijay Kunadian (VK), Renato D. Lopes (RDL), Athanasios Manolis (AM), Girish Mathur (GM), Giuseppe M.C. Rosano (GMCR), Ana Salvati (ASA), Gregg W. Stone (GWS), Jean-Claude Tardif (JCT), Ping Xie (PX), Jian Zhang (JZ), Mohammad Zubaid (MZ), William T. Abraham (WTA), Wael Abuzeid (WA), Rasha Al-Bawardy (RAB), Thomas Alexander (TAL), Stefan D. Anker (SDA), John J. Atherton (JJA), Andrea Baer (AB), Rakesh Bhadade (RB), William E. Boden (WEB), Gabriela Borrayo Sanchez (GBS), Javed Butler (JB), Edina Cenko (EC), Edith H. Chavez (EHC), Vijay Chopra (VC), Andrew J.S. Coats (AJSC), Marcelo Di Carli (MDC), Jianzeng Dong (JD), Jan Fedacko (JF), Gerasimos Filippatos (GF), Abdoul Kane (AK), Muhammad Shahzeb Khan (MSK), Pablos Lamelas (PL), Michael Lee (ML), Haroldo Lopez (HL), Angela H.E.M. Maas (AHEMM), Mpiko Ntsekhe (MN), Pat O'Donnell (POD), Gian Piero Perna (GPP), Miguel Quintana (MQ), Bagirath Raghuraman (BR), Ruchit Shah (RS), Vladimir Ullauri (VU), Sarah Zaman (SZ), Jose Luis Zamorano (JLZ), Yuhui Zhang (YZ), Sheng-hua Zhou (SZH), Shelley Zieroth (SZI), Rod Zimmermann (RZ), Habib Gamra (HG), Maria Ines Sosa Liprandi (MISL), Juan-Carlos Kaski (JCK)

FJP: in the past 36 months, consulting fees from UCB, MSD, and Daiichi Sankyo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, Servier, Novartis, MSD, and Daiichi Sankyo; participation on advisory boards for Daiichi Sankyo and Vifor; leadership roles as Board Member of the NCD Alliance and Past President of the ESC and WHF.

MG: in the past 36 months, consulting fees from Pfizer, Amgen, Bayer, and Boehringer Ingelheim; payment or honoraria for lectures/educational events from Zoll; participation on an advisory board for Merck.

DC: has received honoraria for lectures/educational events and support for meeting attendance/travel from Menarini.

CKC: in the past 36 months, grants or contracts from an NHMRC Investigator grant; payment or honoraria for lectures/educational events from Amgen, Novo Nordisk, AstraZeneca, Pfizer, Eli Lilly, and Perpetual; a patent planned, issued, or pending on compositions for the treatment of hypertension (Patent No. 10369156); leadership roles with the Western Sydney Local Health District and the National Heart Foundation.

LHWG: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier, Novartis, and GSK; support for attending meetings and/or travel from Servier, Novartis, and GSK.

DI: holds a leadership role as Chair of the Health Equity Committee, American College of Cardiology.

AS: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL, Edwards, Eli Lilly, Glaxo Smith Kline, HealthEd, Inside Practice, Menarini, Merck Sharp and Dohm, Moderna, Mylan, National Cardiac Monitoring Incorporated, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Servier, Viartis, Vifor; support for attending meetings and/or travel from Pharmacosmos, Vifor, AstraZeneca, Boehringer Ingelheim, Novartis; participation on a Data Safety Monitoring Board or Advisory Board for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL, Edwards, Eli Lilly, Glaxo Smith Kline, HealthEd, Inside Practice, Menarini, Merck Sharp and Dohm, Moderna, Mylan, National Cardiac Monitoring Incorporated, Novartis, Novo Nordisk, Otsuka, Pfizer, Roche, Sanofi, Servier, Viartis, Vifor; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Writing Committee for Cardiac Society/National Heart Foundation Guidelines for the Management of Heart Failure in Australia; stock or stock options for National Cardiac Monitoring Incorporated, National Cardiac Monitoring Australia Pty Ltd.; receipt of equipment, materials, drugs, medical writing, gifts or other services from Novartis, CSL, Vifor, Mylan, Roche.

BLA: in the past 36 months, consulting fees from Amgen, Bayer, HLS Therapeutics, Merck, Novartis, Novo Nordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer; participation on a Data Safety Monitoring Board or Advisory Board for Amgen, CHRC CPD Network Association, HLS Therapeutics, Novartis, Novo Nordisk; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Canadian Society of Vascular and Preventive Medicine, Editorial Board Journal of European Society of Preventive Cardiology..

GA: in the past 36 months, grants or contracts from CLS; consulting fees from Novo Nordisk (paid to him) and Amarin (paid to his institution); payment or honoraria for lectures/educational events from Menarini.

AAM: in the past 36 months, grants or contracts from MSD (paid to institution); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Novartis, Chiesi, Roche, Servier; support for attending meetings

and/or travel from Adium; participation on a Data Safety Monitoring Board or Advisory Board for Chiesi; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for President Mexican Society of Cardiology.

OB: in the past 36 months, grants or contracts from Bayer (research grant paid to institution); leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Chair of the UKCRC Clinical Trial Units Registration Review Committee (unpaid).

EG: in the past 36 months, consulting fees (paid to him) from Roche Diagnostics, Brahms Deutschland, and Apontis Deutschland; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche Diagnostics, Bayer Vital, Daiichi Sankyo, Brahms Deutschland, Apontis Deutschland (paid to him), and AstraZeneca (paid to his institution); a leadership role as Chair of the Working Group on Chest Pain of the German Society of Cardiology and member of the ESC Biomarker Group.

RDL: in the past 36 months, grants or contracts (paid to his institution, Duke University) from Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Novartis, Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Alnylam, Roche, Bayer, VeraDermics, Priovant Therapeutics, Basilea Pharmaceutica, Theravance Biopharma, and Cytokinetics; consulting fees (paid to him) from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novo Nordisk, Novartis, and Pfizer; payment or honoraria for lectures/educational events (paid to him) from Pfizer, Novartis, Novo Nordisk, and Bristol Myers Squibb.

AM: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Menarini; support for attending meetings and/or travel from Menarini.

GMCR: in the past 36 months, consulting fees from Alnylam, AstraZeneca, Servier, and Vifor Pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alnylam, AstraZeneca, Boehringer Ingelheim, Medtronic, Servier, Viatris, and Vifor Pharma; a leadership role as Chair of the Board of Trustees, Heart Success Foundation; other financial support from Ricerca Corrente, Italian Ministry of Health.

ASA: in the past 36 months, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for President of the Argentine Cardiology Foundation until December 2025.

GWS: in the past 36 months, grants or contracts (paid to Mount Sinai Hospital) from Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems, Philips, Pulnovo, and V-Wave; consulting fees (personal payments) from Occlutech, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio, HeartFlow, Colibri, Bioventrix, Abbott, Remote Cardiac Enablement, Aria, Adona Medical, Curie Bio, Cardiac Success, Valfix, Zoll, Shockwave, HighLife, Elucid Bio, Allevant, FBR Medical, MedHub, Biotyx Medical, Ablative Solutions, and

DLong Medtech; stock or stock options in Cardiac Success, Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Valfix, Xenter, and Vascentis.

JCT: in the past 36 months, grants or contracts (paid to his institution) from Amgen, Boehringer Ingelheim, Ceapro, DalCor Pharmaceuticals, Merck, Novartis, Novo Nordisk, and Verve Therapeutics; consulting fees (paid to him) from DalCor Pharmaceuticals and Merck; honoraria from Pendopharm; patents (assigned to his institution) on pharmacogenomics-guided CETP inhibition and on the use of colchicine after myocardial infarction (rights waived, no financial benefit); a minor equity interest in DalCor Pharmaceuticals.

WTA: in the past 36 months, consulting fees from Cardiac Dimensions, Johnson & Johnson, and Zoll Respocardia; participation on scientific advisory boards or executive committees for AquaPass, Cordio Medical, CVRx, Innoventric, Relief Cardiovascular, Sensible Medical, and Vectorious Medical Technologies; a patent for a mobile ultra-wideband radar for monitoring thoracic fluid levels and cardio-respiratory function (Publication No. US2021/0290074 A1); a board membership role with BioVentrix; stock options in Bioventrix, Cardiac Dimensions, and Johnson & Johnson.

WA: has received consulting fees from Boston Scientific and support for travel from Medtronic, Abbott, and Edwards.

RAB: in the past 36 months, honoraria from Amgen, Boston Scientific, Medtronic, Meril, and Abbott; support for attending meetings and/or travel from Amgen, Medtronic, and Abbott.

TAL: in the past 36 months, honoraria from Sun Pharmaceuticals/Medtronic, Torrent Pharmaceuticals, and AstraZeneca; support for travel from Medtronic; leadership roles as Co-Chairman of STENT Save a Life and Director of STEMI India.

SDA: grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and/or lectures from Actimed, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Occlutech, Pfizer, Regeneron, Repairon, Scirent, Sensible Medical, Servier, Vectorious, and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents.

JJA: in the past 36 months, grants or contracts (payments to his employer) as Principal Investigator for FINEARTS-HF, VICTOR, POSIEDON, HERMES, MARITIME-HF, and ZENITH; consulting fees from Boehringer Ingelheim, Sanofi-Genzyme, Seqirus, and Viatris advisory boards; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, and Sanofi-Genzyme; support for attending meetings and/or travel from Bristol-Myers Squibb, Novo

Nordisk, Viatris, and Vifor Pharma; participation on advisory boards for AstraZeneca, Boehringer Ingelheim, Echo-IQ, Lilly, Novo Nordisk, Sanofi, Seqirus, and Viatris; a leadership role on the Australian MBS Review Advisory Committee.

WEB: in the past 36 months, participation on a Data Safety Monitoring Board or Advisory Board for 2 DSMBs for VA RCTs in official research capacity (unpaid).

JB: in the past 36 months, consulting fees (paid to him) from Abbott, Adaptyx, Amgen, Anumana, AskBio, AstraZeneca, Bayer, Berlin Heals, Boehringer Ingelheim, Boston Scientific, BridgeBio, Bristol Myers Squibb, Cardiac Dimensions, CSL Vifor, Chugai, CVRx, Cytokinetics, Daxor, Diastol, Edgewise, Edwards, Impulse Dynamics, Imbria, Levator, Lexicon, Eli Lilly, Kardigan, Medtronic, Merck, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Recordati, Regeneron, Reprieve, Roche, Saillant, Salubris, Servier, Scirent, Secretome, TekkunLev, Tenex, and Zoll; payment or honoraria for lectures/educational events from Boehringer Ingelheim, Merck, and Bayer.

EC: holds unpaid leadership roles as Chairperson of the ESC Working Group on Coronary Pathophysiology and Microcirculation and as a junior member of the EC of the Azure programme.

VC: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Sanofi, Boehringer Ingelheim, Bayer, Pfizer, Mankind, Lupin, Cipla, and Novo Nordisk; support for attending meetings and/or travel from Mankind, Lupin, and Cipla.

AJSC: in the past 36 months, consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, GSK, Novartis, Novo Nordisk, Servier, Vifor, Actimed, Cardiac Dimensions, Corvia, ESN Cleer, Impulse Dynamics, Zoll, Viatris, and Pulnovo.

MDC: in the past 36 months, grants or contracts (institutional, investigator-initiated) from GE Healthcare, Sun Pharma, and Gilead Sciences; consulting fees (paid to him) from GE Healthcare, MedTrace Pharma, ValoHealth, Sofie, and Bitterroot Bio; other institutional service agreements with Intellia Therapeutics and Xylocor Therapeutics.

JF: in the past 36 months, grants or contracts from EU/Horizon Europe (awarded to a company owned by the author; no direct personal payment) and from clinical trial sponsors under contracts with an s.r.o. company (payments not made directly to him); payment or honoraria for lectures/educational events from Swixx BioPharma, Amgen, Roche, and Novo Nordisk; participation on advisory boards/steering committees for Amgen, AstraZeneca, NewAmsterdam Pharma, Boehringer Ingelheim, Novo Nordisk, and Eli Lilly; no stock or stock options in pharmaceutical companies.

GF: in the past 36 months, grants or contracts from European Commission; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, Boehringer Ingelheim, Servier, Novartis, Genesis Pharma; participation on a Data Safety Monitoring Board or Advisory Board for Bayer, Novo Nordisk, Cytokinetics, Boehringer Ingelheim; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Heart Failure Association, JACC Heart Failure, European Journal of Heart Failure; trial committee membership fees from Medtronic, Bayer, Boehringer Ingelheim, Vifor, Amgen, Servier, Impulse Dynamics, Cardior, MSD, AstraZeneca, Cytokinetics, Novo Nordisk.

MSK: in the past 36 months, research support from the NIH, AHA, and Merck; consulting fees from Bayer, Boehringer Ingelheim, and Novartis.

MN: in the past 36 months, grants or contracts from the La Dûq Foundation/NHLBI (USA), the Novo Nordisk Foundation/South African Medical Research Council, and the National Institutes of Health (USA); support for attending meetings and/or travel to a conference in Europe.

SZ: in the past 36 months, grants or contracts from an NHMRC Investigator Grant (ID 2043180) and a National Heart Foundation Future Leader Fellowship Grant (ID 107282); payment or honoraria for lectures/educational events from Novartis (2024), Boston Scientific (2024), and Amgen (2025); support for travel (<\$1000, flights/hotel) from Novartis to attend a conference in Melbourne; other non-financial interests: the Marie Krogh Women in Science prize, awarded by Novo Nordisk (2025).

JLZ: has received speaker honoraria from Viatrix, Novartis, Philips, and Novo Nordisk.

SZI: in the past 36 months, consulting fees and honoraria from advisory-board or speaker engagements with AskBio, Abbott, Alnylam, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, CSL Vifor, Cytokinetics, Eli Lilly, GSK, Medtronic, Merck, Novartis, Novo Nordisk, SunPharma, Pfizer, and Viatrix; membership on clinical trial committees for studies sponsored by AstraZeneca, Boehringer Ingelheim, Cardiac Dimensions, Cytokinetics, Merck, Novo Nordisk, Pfizer, and Salubris Bio; non-industry roles with CCS, CHFS, Charité, CPD Network, CSN, EOCI, iHF, Liv, LMC Healthcare, Medscape, Meducation, Radcliffe, ReachMD, Sciarc, and the Translational Medicine Academy; participation on an advisory board for Pfizer; leadership roles as Chair of the iCARDIO Alliance Guideline Advisory Board and member of the ACC Board of Governors.

HG: in the past 36 months, consulting fees from Servier; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier, Menarini, and AstraZeneca; support for attending meetings and/or travel from Servier and Novo Nordisk.

MISL: in the past 36 months, grants or contracts from Janssen, Windtree Therapeutics, and CPC Clinical Research; consulting fees and honoraria from GlaxoSmithKline; support for attending

meetings and/or travel from Bayer and Johnson & Johnson.

JCK: received travel support from the Menarini Foundation Italy and holds the role of Past Chairman of the ESC Working Group on Cardiovascular Pharmacotherapy.

GSW, AD, RH, NJ, VK, GM, MZ, AB, RB, GBS, EHC, ML, AHEMM, POD, MQ, BR, VU, YZ, SZH, TA, PX, JZ, JD, AK, PL, HL, GPP, RS, RZ: report no relevant conflicts of interest.

Supplement to the paper: *Pinto FJ et al. iCARDIO Alliance Global Implementation Guidelines on Ischemic Heart Disease 2026. <https://doi.org/10.4081/cardio.2026.112>*